Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 29

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 29
---
 Equity Incentives      Percentage of Equity Granted as of March 17, 2025  
  Subsidiary      Percentage of Subsidiary's Equity Issuable as Equity Incentives                                   as Equity Incentives  
                                                                                       Percentage of Equity Granted as of March 17, 2025  
                                                                                                                    as Equity Incentives  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  AgPlenus                                                                   13.8                                                    8.9  
  Biomica                                                                      12                                                   7.62  
  Casterra                                                                    7.5                                                    3.9  
  Lavie Bio                                                                  10.5                                                    8.8  

Grants under our subsidiaries’ equity incentive plans may
qualify for favorable treatment under the tax law provisions of the United States or Israel.

The share-based payments under our subsidiary equity incentive plans are presented as
non-controlling interests in the financial statements and were valued at approximately $1.4 million in 2024, as detailed in Note 17g to
the financial statements included in this Annual Report under Item 18.

85

C. Board
Practices

Board of Directors

Under the Companies Law and our articles of association, the supervision
of the management of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all
actions that are not specifically granted to our shareholders or to executive management. Our Chief Executive Officer (referred to as
a “general manager” under the Companies Law) is responsible for our day-to-day management. Our Chief Executive Officer is
appointed by, and serves at the discretion of, our board of directors, subject to the employment agreement that we have entered into with
him. All other executive officers are appointed by the Chief Executive Officer and are subject to the terms of any applicable employment
agreements that we may enter into with them.

Under our articles of association and the Companies Law, our board
of directors must consist of not less than three and no more than seven directors. Currently our board of directors consists of six directors.

Our directors are elected annually, by a simple majority vote of
holders of our voting shares participating and voting at the annual meeting of our shareholders, for a one-year term, from the annual
general meeting of our shareholders at which they are elected until the next annual general meeting and until their respective successors
are elected and qualified or until their earlier removal by our shareholders at a